Protocol Ledger

NCT04108156 · Phase III · ACTIVE NOT RECRUITING

A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate

Interventional Phase III clinical trial protocol NCT04108156 sponsored by Roche / Genentech in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-09-30 Enrollment: 672 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04108156
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)672 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04108156
Protocol FieldVerified Registry Value
NCT IdentifierNCT04108156
Consolidated Lead SponsorRoche / Genentech
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment672 participants (ACTUAL)
Registered Start Date2019-09-30
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI